The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACIU | -9.12% | -41.51% | -10.17% | -81% |
| S&P | +15.06% | +95.03% | +14.29% | +211% |
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
The FDA has granted a Fast Track Designation to its Alzheimer's disease vaccine candidate.
MIxed results for the company's Alzheimer's disease candidate are good enough for the market today.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.58M | 108.2% |
| Gross Profit | -$0.64M | 0.0% |
| Market Cap | $200.85M | -49.3% |
| Market Cap / Employee | $1.17M | 0.0% |
| Employees | 172 | 6.8% |
| Net Income | -$25.65M | -1.9% |
| EBITDA | -$22.75M | -0.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $32.31M | -43.7% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.87M | 72.3% |
| Short Term Debt | $1.31M | 70.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -23.24% | 7.8% |
| Return On Invested Capital | -34.78% | -12.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$21.22M | -126.3% |
| Operating Free Cash Flow | -$20.73M | -125.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.17 | 1.55 | 1.52 | 1.67 | -28.53% |
| Price to Sales | 8.14 | 8.57 | 5.77 | 6.12 | -73.14% |
| Price to Tangible Book Value | 3.55 | 2.54 | 2.75 | 3.56 | -0.54% |
| Price to Free Cash Flow TTM | 8.39 | 7.57 | 3.63 | 3.60 | - |
| Enterprise Value to EBITDA | 22.02 | -4.51 | -1.39 | -2.23 | -75.51% |
| Free Cash Flow Yield | 11.9% | 13.2% | 27.6% | 27.8% | - |
| Return on Equity | -30.6% | -36.4% | -43.3% | -50.6% | 8.86% |
| Total Debt | $3.65M | $5.99M | $5.85M | $6.18M | 71.97% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
